Adverse Effects of Treatment with Porcine Factor VIII

Summary

In the last 10 years 63 courses (283 infusions) of porcine FVIII were given to 25 hemophiliacs with high titer alloantibodies and to 5 patients with autoantibodies to factor VIII. Although the product was in general clinically efficacious, adverse effects of treatment were more frequent and severe than previously reported. After 63 courses there was a median percentage fall in baseline platelet count of 54% (range 8-86%); for 10 courses (16%), thrombocytopenia was severe or moderately severe (<100 × 10⁹/1), with nadirs of platelet count ranging from 10 to 99 × 10⁹/1 (median 67). Allergic reactions were seen in 15 of 30 patients (50%), in 20 of 63 courses (32%), more frequently but not exclusively after the first infusion. Relatively mild symptoms (fever, Hushing, urticaria, shivering) occurred in 15 courses; 5 courses, however, were accompanied by more severe anaphylactoid reactions, 2 of which required resuscitation therapy. Allergic reactions were observed both in patients pretreated with steroids or anti-histamines (in 7 of 18 courses, 39%) and in nonpretreated patients (in 13 of 45 courses, 29%). In conclusion, adverse reactions are frequent after porcine FVIII (in 30 of 63 courses, 47%), and can occur also with infusions subsequent to the first. Hence, the recently proposed use of porcine FVIII as home treatment should be implemented with caution.

• REFERENCES

• 1 Conard J. Inhibitors of blood coagulation. In: Blood Coagulation and Haemostasis Thompson JM. (ed). Churchill Livingstone; Edinburgh: 1980: 212-223
• 2 Middleton S. Polyelectrolytes and preparation of factor VIII: C. In: Unresolved Problems in Hemophilia Forbes CP, Lowe GD. (eds). MTP Press; Lancaster: 1982: 109-120
• 3 Gatti L, Mannucci PM. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemostas 1984; 51: 379-384
• 4 Kemoff PBA, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham EGD. Clinical experience with polyelectrolyte fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984; 63: 31-41
• 5 Ciavarella N, Antoncecchi S, Ranieri P. Efficacy of porcine factor VIII in the management of hemophiliacs with inhibitors. Br J Haematol 1984; 58: 641-648
• 6 Brettler DB, Forsberg AD, Levine PH, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H. and the Cooperating Investigators The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. Arch Intern Med 1989 149. 1381-1385
• 7 Kernoff PBA. The clinical use of porcine factor VIII. In: Recent Advances in Hemophilia Care Kasper KC. (ed) Alan R. Liss Inc; 1990: 47-56
• 8 Hay CRM, Laurian Y, Verroust F, Preston FE, Kemoff PBA. Induction of immune-tolerance in patients with haemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood 1990; 76: 882-886
• 9 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni JC, Green D, Hampton JR, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh 1975; 34: 869-872
• 10 Miettinen OS. Estimability and estimation in case referent studies. Am J Epidemiol 1976; 103: 226-235
• 11 Erskin JG, Davidson JF. Anaphylactic reaction to low-molecular-weight porcine factor VIII concentrates. Br Med J 1981; 282: 2011-2012
• 12 Colvin BT, Ainsworth M, Buckley C. Experience with highly purified porcine factor VIII in a patient with hemophilia A and a factor VIII inhibitor. Clin Lab Haemat 1983; 5: 55-59
• 13 Altieri D, Capitanio AM, Mannucci PM. vWF contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Hematol 1986; 63: 703-714